NUVL•prnewswire•
Nuvalent Announces Public Offering of Common Stock
Summary
CAMBRIDGE, Mass., Nov. 17, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that it has commenced an underwritten public offering...
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on November 17, 2025 by prnewswire